> International Association for Biologically Closed Electric Circuits in
> Biomedicine
> The 7th. International Symposium*Marienlyst Conference Center,
> Helsing¯r, Denmark
> Symposium Coordinator: Ms. Karen Wedersoe:e-mail: Dkisisdk@a. . .
> Registration and Accommodations: Ms. Pia Sondergaard; e-mail:
> ps@c. . .
>
> For Immediate Release
>
>
> NEW THERAPY FOR PARKINSON’S DISEASE
> PicoTesla Electromagnetic Fields focused on Pineal Gland result in
> Remarkable Improvements
>
> VOLUNTEERS SOUGHT FOR DEMONSTRATION
>
> Ten patients with Parkinson’s Disease are being sought to participate
> in a demonstration project to be held at Hotel
> Marienlyst between July 19-22, 2001.
>
> The IABC symposium, to be held at Hotel Marienlyst, Helsing¯r, from
> July 19th through the 22nd will be filled with
> surprises. Not only will presenters be discussing the application of
> electrochemical therapy to cancer, a thoroughly
> researched and generally accepted cancer therapy available all over
> China, but also there will be two remarkable
> demonstrations of therapies proven effective in treating Parkinson’s
> Disease and Macular Degeneration.
>
> Beginning in the mid-eighties a long term research project was begun
> by Professor Photios Anninos, Director of the
> Department of Medical Physics at the Democritus University of Thrace,
> Alexandroupolis, Greece. Anninos believed that
> by focusing extremely weak electromagnetic fields on a patients pineal
> gland it could be possible to positively influence
> the secretion of dopamine, serotonin, and melatonin, substances
> believed to be related to the symptoms of PD. He was
> correct in his assumption. Anninos and a number of colleagues
> (Tsagas, DerPappas) experienced a growing number of
> successes in this novel therapy as shown by numerous anecdotal
> articles published over the years in the International
> Journal of Neuroscience.
>
> This therapy is non-invasive and has no serious or lasting side
> effects. A treatment takes approximately ten to fifteen
> minutes and the patient feels nothing. Patients who respond favorably
> to three or four treatments may wish to acquire a
> therapeutic device to continue treatments at home. After six months
> of home treatments some patients have seen all symptoms
> virtually disappear.
>
> Professor Anninos has agreed to demonstrate this device during the
> forthcoming IABC Symposium to be held at the Hotel
> Marienlyst July 19-22, 2001. >
> The number of participants will be limited to the first ten
> volunteers, although a waiting list will be kept in
> case some decide later to opt out.
>
> Area neurologists are cordially invited to attend the symposium.
> Arrangements for hearing Professor Anninos’s
> presentation and witnessing the application of ELF therapy to the ten
> volunteers may be made by contacting Ms. Wedersoe or
> Ms. Sondergaard.
>
> ***************************************************************
>
> NEW TREATMENT FOR MACULAR DEGENERATION DEVELOPED IN U. S.
> MCS THERAPY CAN HALT OR REVERSE PROGRESS OF THE DISEASE
> VOLUNTEERS SOUGHT FOR DEMONSTRATION
>
> Ten Macular Degeneration patients are being sought to participate in a
> demonstration project to be held at Hotel Marienlyst
> between July 19-22, 2001.
>
> The leading cause of blindness in people over the age of 65 is
> age-related macular degeneration, or ARMD. Heretofore very
> little could be done about it except for taking certain
> nutraceuticals, wearing sun glasses, and making appropriate dietary
> changes designed to slow the progress of the disease. Today, however,
> a new therapy is becoming available which has been
> able to stop and even reverse the progress of the disease in some 80
> percent of patients studied.
>
> Microcurrent Stimulation, or MCS, has been used in a number of studies
> done in the U. S. beginning back in the 1980’s and
> extending to the present. While not all patients experience relief,
> in some cases the degree of success experienced has
> been amazing. For example, legendary American golfer, Sam Snead
> entered a research facility with visual acuity of 20/100
> in his good eye. After four days of treatment his visual acuity was
> 20/30, good enough to hit the golf ball once again.
>
> The MCS device used on the 85 year old Mr. Snead was the “Microstim
> 100” invented by Dr. Joel Rossen of Tamarac, Florida.
> Dr. Rossen is presently seeking FDA approval for newer version of his
> device, the Microstim 100i. Dr. Rossen has agreed to
> demonstrate his device during the forthcoming IABC Symposium to be
> held at the Hotel Marienlyst July 19-22, 2001. ARMD
> patients wishing to participate in the demonstration project are
> invited to contact Humlegaarden.
>
> The number of participants will be limited to the first ten
> volunteers, although a waiting list will be kept in case
> some decide later to opt out. One big question needing an answer is,
> “Are there any side effects?”There have been
> no serious side effects experienced in the U. S. after more than
> fifteen years of research conducted on hundreds of patients.
> MCS is totally non-invasive and the Microstim is powered by a little 9
> volt battery. Statistically speaking, of
> the ten volunteers to be treated, eight will respond favorably, the
> two remaining will remain unchanged.
>
> Area ophthalmologists and optometrists are cordially invited to attend
> the symposium. Arrangments for hearing Dr. Rossen’s
> presentation and witnessing the application of MCS to the ten
> volunteers may be made by contacting the staff at humlegaarden. (
> again fill in the blank) to make appropriate arrangements.
>
> +++++++++++++++++++++++++++++++++++++++++++++++++++++
>
> PARKINSON’S DISEASE THERAPY DEVELOPED IN GREECE
> TO BE DEMONSTRATED AT IABC SYMPOSIUM
> VOLUNTEER PD PATIENTS SOUGHT FOR DEMONSTRATION
>
> The IABC symposium, to be held at Hotel Marienlyst, Helsing¯r, from
> July 19th through the 22nd is filled with surprises.
> Not only will presenters be discussing the application of
> electrochemical therapy to cancer, a thoroughly researched and
> generally accepted cancer therapy available all over China, there will
> be two remarkable demonstrations of therapies proven
> effective in treating Parkinson’s Disease and Macular Degeneration.
>
> The IABC was established in 1987 by Swedish Professor Bjorn
> Nordenstrom in cooperation with Chinese Professor Xin Yu-Ling,
> founder and first president of the China Japan Friendship Hospital,
> Bejing. Nordenstrom, professor emeritus at the
> Karolinska Institutet and former chairman of the Nobel Assembly in
> Medicine, discovered the existance within the human
> body of biologically closed electric circuits, or BCEC. From this he
> devised a new means of treating cancer using platinum
> electrodes inserted directly into malignant tumors. In order to
> accelerate the rate of research on this new concept known
> as “electrochemical therapy” or EchT, he sought and won the
> cooperation of Professor Xin to embark upon a nationwide
> research project in China.
>
> More than a decade later Professor Xin and three hundred physicians
> throughout China have demonstrated the efficacy of this
> new and very successful therapy which has been applied to thousands of
> cancer patients. EchT is now becoming available in
> Europe. The first cancer clinic in Denmark to offer this therapy is
> Humlegaarden, located in Humlebaek, and directed by
> Dr. Finn Skott Andersen who, not coincidentally, is serving as IABC
> symposium president as well.
>
> Nordenstrom’s theory of BCEC, while initially focused on developing
> EchT in treating cancer, has many other therapeutic
> applications. Researchers in the U. S. are developing treatments for
> neuromuscular conditions, and have successfully
> developed a treatment for age related macular degeneration, a
> heretofore untreatable condition.[pb_builder]